Overview: Pre-Eclampsia Prediction Panel
Introduction: The Pre-Eclampsia Prediction Panel is a diagnostic tool designed to predict pre-eclampsia risk using serum samples. In India, pre-eclampsia affects ~8-10 percent of pregnancies (higher in primigravida, rural/low-SES due to malnutrition, anemia), causing maternal mortality (~15 percent of maternal deaths) and fetal growth restriction. High morbidity from under-screening leading to delayed low-dose aspirin or monitoring, causing eclampsia, HELLP, or stillbirth. Per obstetrics practices aligned with ICMR, FOGSI, and Indian Society of Perinatology guidelines, the test employs immunoassay for sFlt-1, PlGF, and sFlt-1/PlGF ratio over 1-2 days with high accuracy, valuable for first-trimester or second-trimester risk stratification (high ratio predicts severe disease). This diagnostic falls under prenatal screening and targets high-risk pregnancies (chronic hypertension, prior pre-eclampsia), addressing accurate detection to guide aspirin prophylaxis or frequent monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early prediction and reducing maternal/fetal complications. Its serum-based approach ensures reliable angiogenic marker assessment.
Other Names: Pre-Eclamp Pred Pnl.
FDA Status: FDA approved, CLIA certified for endocrinology/immunology, compliant with 2025 standards.
Historical Milestone: sFlt-1/PlGF ratio standard since 2010s; in India, expanding in high-risk antenatal care.
Purpose: The test assesses 3 parameters including sFlt-1 to guide pre-eclampsia risk prediction, assess angiogenic imbalance, inform prophylaxis.
Test Parameters: 1. sFlt-1, 2. PlGF, 3. sFlt-1/PlGF Ratio.
Pretest Condition: Fasting 10-12 hours recommended; patients should be high-risk pregnant.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on gestational age, risk factors.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected pre-eclampsia including eclampsia, benefits of prediction, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and calculate ratio within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: High sFlt-1/PlGF ratio (>38) predicts pre-eclampsia, necessitating specialist input.
Specialist Consultation: Fetal medicine specialists should be consulted for management.
Additional Supporting Tests: Doppler ultrasound, blood pressure monitoring for confirmation.
Test Limitations: Predictive (not diagnostic); comprehensive approach required.
References: Indian Journal of Obstetrics and Gynaecology 2024, Maternal Studies India 2023.
